Vitamin D or placebo in treatment of uterine leiomyoma
- Conditions
- Volume and duration of mensturation, Leiomyoma of uterus, size.Irregular menstruation, Leiomyoma of uterus, unspecified, Excessive and frequent mensturation with regular or irregular cycleN92.0, N92
- Registration Number
- IRCT2014121511019N4
- Lead Sponsor
- Vice Chancellor for Research and Technology, Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 40
Age between 20 and 45 years, having one or more uterine fibroids, the largest be 3 cm based on ultrasound, vitamin D and 25-hydroxyvitamin D concentrations lower than 75 nmol per liter or 30 ng/ml.
Exclusion criteria: Leiomyoma with acute symptoms which requiring to immediate surgical intervention, liver or kidney disorders, cancer of the uterus, cervix and ovarian, adnexal mass, endometrial lesions such as polyps on ultrasound, use of hormonal therapy in the last three months, pregnancy, lactation or the desire to become pregnant during the study period, delivery within the last six months, uterine myoma in size more than 12 cm, the size of the uterine leiomyoma more than 20 weeks, history of gastrointestinal problems, especially malabsorption syndrome.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Size of Uterine Liomyoma. Timepoint: 4 months after intervention. Method of measurement: Sonography study.
- Secondary Outcome Measures
Name Time Method Menstrual bleeding and related symptoms. Timepoint: 2, 3 and 4 months after intervention. Method of measurement: Pictorial Blood Loss Assessment Chart (PBAC) and Visual analog scale (VAS).